The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 27, 2023
Filed:
Feb. 03, 2020
Janssen Pharmaceutica NV, Beerse, BE;
Ricardo Attar, Lawrenceville, NJ (US);
Francois Gaudet, Spring House, PA (US);
Mark Tornetta, Collegeville, PA (US);
Alexey Teplyakov, Phoenixville, PA (US);
Mark Mendonca, Philadelphia, PA (US);
Suzanne Edavettal, San Diego, CA (US);
Kodandaram Pillarisetti, Spring House, PA (US);
Nathan Majewski, Warrington, PA (US);
Yingzhe Li, Dresher, PA (US);
Leopoldo L. Luistro, III, Lansdale, PA (US);
Diana Chin, Norwood, PA (US);
Janssen Pharmaceutica NV, Beerse, BE;
Abstract
Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.